Quick Take
Imara (IMRA) has filed to raise $86.25 million in an IPO of its common stock, according to an A-1 registration statement.
The company is a clinical stage firm developing treatments for genetic disorders of hemoglobin.
IMRA is an early Phase 2 biopharma with an expected potential catalyst in late 2020 for its lead candidate.
I’ll provide a final opinion when we learn more IPO details from management.
Company & Technology
Boston, Massachusetts-based Imara was founded to develop and commercialize therapeutics for patients suffering from hemoglobinopathies.
Management is headed by President